Melbourne, Australia January 28, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias. Under the terms of the agreement, STA will be responsible for obtaining marketing authorization and
![Arctica Specialised Therapeutics](https://stabiopharma.com/wp-content/uploads/2021/03/stabio-logo.png)